MiniMed Group Consensus Price Target Increased by 20.43% to $26.24
The average one-year price target for MiniMed Group (NASDAQGS:MMED) has been revised to $26.24 / share as of September 15, 2026. This is an increase of 20.43% from the prior estimate of $21.79 dated August 25, 2026. These figures represent aggregate analyst targets compiled from independent researchers and do not constitute a recommendation by Fintel.
The latest targets range from a low of $21.21 to a high of $29.40 / share. The average price target represents an increase of 19.23% from the latest reported closing price of $22.01 / share as of September 14, 2026. The current median target of $26.52 has increased from the prior median of $21.42.
This update marks a consecutive target revision direction of increased for 3 times. Looking at the target history, the mean target was $21.33 on June 30, 2026, $21.42 on August 4, 2026, $21.79 on August 28, 2026, and reached $26.24 on September 15, 2026. The observed twelve-month high mean target is $26.24 as of September 15, 2026, while the observed twelve-month low mean target is $21.33 as of June 30, 2026. This represents a target change of +23.04% since the 90-day baseline date of June 9, 2026.
For context, MiniMed Group reported its latest earnings on September 1, 2026, with an actual EPS of 0 compared to an estimate of 0.0952, representing a surprise of -100.00%. Actual revenue was $843,000,000.00 against an estimate of $843,606,708.00, a surprise of -0.07%.
Recent analyst rating actions include Morgan Stanley maintaining an Overweight grade on September 3, 2026. Mizuho, UBS, and B of A Securities also maintained their respective Outperform, Buy, and Buy grades on September 2, 2026. As of the September 1, 2026 recommendation period, the company had 18 total recommendations, with 88.9% positive, 11.1% hold, and 0.0% negative.
Within the Building Products GICS sub-industry, which covers 34 companies, 17 companies saw raised targets, 10 were lowered, and 7 were unchanged. The sub-industry median revision percent was +0.04% with a median implied change of +47.62%.
The peer group exhibited divergent target revisions, ranging from a decrease of -7.93% for AtaiBeckley to an increase of +6.65% for GH Research, while all three peers maintained positive implied changes.
| Company name | Target revision | Implied change |
|---|---|---|
| AtaiBeckley | -7.93% | +36.51% |
| COMPASS Pathways plc - Depositary Receipt | 0.00% | +60.26% |
| GH Research | +6.65% | +52.62% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.